Dr. G. Bozet, MD
Histopathological Diagnosis of NASH
Fatty acid beta oxidation is a predominant bioenergetic pathway in mammals. Substantial investigations have demonstrated that fatty acid.....
Accuracy of serum biomarkers versus liver biopsy
This first study on Croatian patients with NAFLD was conducted to evaluate the diagnostic performance of various biomarkers for steatosis, fibrosis, and inflammation in comparison to a liver biopsy.....
Read MoreAccuracy of serum biomarkers versus liver biopsyAttenuation coefficient liver to spleen ratio and determination of hepatic steatosis
The aim of the study was to assess ultrasound attenuation coefficient in adult liver and spleen. The authors calculated attenuation coefficient liver to spleen ratio.....
Read MoreAttenuation coefficient liver to spleen ratio and determination of hepatic steatosisInvestigating hepatocellular inflammasome activation
Inflammasome activation followed by maturation has been observed in both preclinical models and NASH patients suggesting the crucial importance of inflammasome activation in NAFLD progression......
Read MoreInvestigating hepatocellular inflammasome activationPurification and isolation of hepatic stellate cells
In an activated form, human hepatic stellate cells are the drivers of fibrosis following chronic liver injury. In NASH specifically, activated human hepatic stellate cells are drivers of induction and progression of fibrogenesis. .....
Read MorePurification and isolation of hepatic stellate cellsA liver targeted gene delivery system
NASH is characterized by multiple underlying genetic mutations, with no approved cure to date. Gene therapies that target those genetic mutations may play a major role in treating this disease, once delivered specifically to the hepatocytes. .....
Read MoreA liver targeted gene delivery systemMAFLD/NAFLD biopsy-free scoring systems
The current clinical practice is urged to incorporate biopsy-free scoring systems that demonstrate adequate performance metrics for the accurate detection of patients with MAFLD and underlying .....
Read MoreMAFLD/NAFLD biopsy-free scoring systemsNAFLD-MAFLD: is there a consensus-on-consensus methodology?
The so far well-received new name and redefinition of fatty liver disease have generated debates. The most common argument is that .....
Read MoreNAFLD-MAFLD: is there a consensus-on-consensus methodology?Poor Sleep Quality and risk of NAFLD
The impact of changes in sleep duration and sleep quality over time on the risk of NAFLD is not known. In a cohort study included 86,530 Korean adults.....
Read MorePoor Sleep Quality and risk of NAFLDCellular Senescence and NAFLD
In this review, C. Engelmann C and F. Tacke (Campus Virchow-Klinikum and Campus Charité Mitte, Charité-Universitätsmedizin Berlin, Germany) critically discuss the currently .....
Read MoreCellular Senescence and NAFLDNon-alcoholic fatty liver disease in irritable bowel syndrome: More than a coincidence?
Recently, there has been interest in the apparent co-incidence of NAFLD in patients with IBS mainly driven by improved understanding of their shared risk factors and pathophysiology H. Purssell et al. (Manchester University NHS Foundation Trust, UK)......
Read MoreNon-alcoholic fatty liver disease in irritable bowel syndrome: More than a coincidence?Chronopharmacology, or timing of drug administration in NASH
Liver homeostasis is strongly influenced by the circadian clock. Disruption of the clock has been heavily implicated in the pathogenesis of NAFLD and NASH. There has been little consideration of the application of chronopharmacology in NASH, a strategy whereby.....
Read MoreChronopharmacology, or timing of drug administration in NASH
SUBSCRIBE & FOLLOW US
SUBSCRIBE TO OUR MONTHLY NEWSLETTER TO GET THE LATEST UPDATES